Nasus Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	0.2	0.28	0.19	0.15
Cash & Short-Term Investments	0.2	0.28	0.19	0.15
Cash Growth	-77.44%	47.15%	25.32%	-
Other Receivables	-	0.12	-	-
Receivables	-	0.12	-	-
Prepaid Expenses	0.06	0.03	0.23	0.25
Restricted Cash	0.03	0.03	0.02	0.02
Total Current Assets	0.29	0.46	0.44	0.42
Long-Term Deferred Charges	0.35	0.26	-	-
Total Assets	0.64	0.72	0.44	0.42
Accounts Payable	0.66	0.65	0.66	0.77
Accrued Expenses	1.18	0.99	0.62	0.35
Short-Term Debt	2.56	1.8	2.46	1.57
Other Current Liabilities	0.55	0.49	0.51	0.51
Total Current Liabilities	4.95	3.93	4.24	3.2
Total Liabilities	4.95	3.93	4.24	3.2
Common Stock	0.02	0.02	0.02	0
Additional Paid-In Capital	9.58	9.43	7.32	7.29
Retained Earnings	-13.92	-12.66	-11.13	-10.08
Shareholders' Equity	-4.31	-3.21	-3.8	-2.79
Total Liabilities & Equity	0.64	0.72	0.44	0.42
Total Debt	2.56	1.8	2.46	1.57
Net Cash (Debt)	-2.36	-1.52	-2.26	-1.42
Net Cash Per Share	-0.32	-0.22	-0.32	-0.21
Filing Date Shares Outstanding	7.36	7.36	6.89	6.89
Total Common Shares Outstanding	7.36	7.36	6.89	6.89
Working Capital	-4.66	-3.47	-3.8	-2.79
Book Value Per Share	-0.59	-0.44	-0.55	-0.40
Tangible Book Value	-4.31	-3.21	-3.8	-2.79
Tangible Book Value Per Share	-0.59	-0.44	-0.55	-0.40

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q